StageZero Life Sciences has entered a collaboration to offer its multi-cancer blood test, Aristotle, to DiagnoseAtHome’s (DAH) patients in the US and Canada. 

Aristotle is a next-generation test based on StageZero’s messenger ribonucleic acid (mRNA) gene expression technology platform.

It is claimed to be the first-ever mRNA multi-cancer panel that can test for various cancers from a single blood sample concurrently with increased sensitivity and specificity for each cancer. 

StageZero noted that the Aristotle test identifies gene expression profiles that indicate specific cancers by interrogating mRNA from a whole blood sample. 

Furthermore, it can screen for molecular signatures linked to various individual cancers, including breast, ovarian, endometrial, colorectal, liver, stomach and prostate cancers.

StageZero Life Sciences chairman and CEO James Howard-Tripp said: “Our partnership with DiagnoseAtHome allows greater access to early cancer screening for their many clients and broadens the availability of Aristotle in Canada and the USA. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“Growing our patient base and expanding the availability of our early cancer test is a key pillar in our Growth Strategy.”

DAH provides accessible at-home health and lab testing solutions, permitting organisations, businesses and healthcare providers to deliver safe and precise lab testing to patients without the need for in-person visits to the laboratory. 

DiagnoseAtHome founder Dr Ian Plener said: “By onboarding Aristotle to the DAH platform, we are better able to provide our patients and providers with a novel approach to early cancer screening. 

“Growing our laboratory network will further enhance the breadth of curated laboratory solutions available to our growing patient and provider base.”